Fluidigm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
Fluidigm Corporation (Nasdaq:FLDM) announces participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. CEO Chris Linthwaite and CFO Vikram Jog will provide updates on the company's business strategy and financial performance. A pre-recorded fireside chat will be available on demand on November 22, 2021, at 10:00 a.m. ET, followed by virtual one-on-one meetings on November 30, 2021. The webcast of the chat will be archived for 90 days on Fluidigm's investor website, emphasizing its commitment to advancing health insights through innovative research solutions.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will participate in investor meetings and present updates regarding Fluidigm’s business strategy and financial performance at the following investor event:
- Piper Sandler 33rd Annual Virtual Healthcare Conference. A pre-recorded fireside chat will be made available on demand Monday, November 22, 2021, at 10:00 a.m. ET. Management will be available Tuesday, November 30, 2021, for virtual one-on-one meetings.
A live webcast of the company’s fireside chat and subsequent replay will be available in the Events & Presentations section of the Fluidigm® investor website. The webcast will be archived for 90 days following the live presentation.
About Fluidigm
Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
Available Information
We use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Contact:
Investors:
Peter DeNardo
415 389 6400
ir@fluidigm.com
FAQ
What is Fluidigm's participation in the Piper Sandler Virtual Healthcare Conference?
When will Fluidigm's management be available for virtual meetings?
Where can I watch Fluidigm's fireside chat?
How long will the webcast of Fluidigm's fireside chat be available?
What technologies does Fluidigm focus on for health insights?
